Clinical Accelerator, a leading CRO specializing in early-stage First-in-Human (FIH) and early feasibility MedTech studies, is pleased to announce its collaboration with Relief Cardiovascular on the FIH clinical trial of the Relief System. Full study approval has now been granted in Georgia, and preparations are underway to initiate the trial.
Innovating Fluid Management in Heart Failure
The trial will evaluate the Relief System, the world’s first transcatheter smart implant, which dynamically monitors and modulates cardiac preload and congestion. Unlike legacy passive monitoring systems, the Relief System implant autonomously captures multiparametric and hemodynamic data to guide device-driven pressure relief to optimize fluid balance and diuretic efficiency in patients with chronic heart failure. With its ability to monitor and control the implant via a remote cloud interface, the Relief System represents a new paradigm in heart failure: direct, tunable decongestion driven by a data-driven therapeutic implant.
A Strategic Location for Early-Stage Trials
Georgia’s robust clinical infrastructure combined with Clinical Accelerator’s regional experience enables rapid start-up, high-quality enrollment, and reliable data management. Clinical Accelerator will act as the CRO, overseeing regulatory liaison, site coordination, and trial operations, ensuring alignment with Relief Cardiovascular’s strategic objectives.
Next Steps
With study approval now in place, Clinical Accelerator and Relief Cardiovascular will move forward with site initiation and patient enrollment. The study is expected to generate valuable insights into the system’s clinical performance and therapeutic potential.
About Clinical Accelerator
Clinical Accelerator is an independent, academically connected, full-service CRO operating in Central and Eastern Europe and Central Asia. The company specializes in First-in-Human and early-phase studies for innovative MedTech and biotech companies, offering accelerated timelines, cost efficiency, and access to experienced clinical sites.
www.clinicalaccelerator.com
About Relief Cardiovascular
Relief Cardiovascular is a privately held company developing a novel transcatheter platform for improving fluid management in heart failure. Its transcatheter smart implant enables pressure-guided therapy, targeting patients who are resistant to conventional diuretic treatment.
www.reliefcardio.com